Insufficient scRNA-seq data for expression of NPFF at single-cell level.
Insufficient scRNA-seq data for expression of NPFF at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
bladder | 100% | 181.00 | 21 / 21 | 0% | 0 | 0 / 504 |
breast | 100% | 176.03 | 459 / 459 | 0% | 0 | 0 / 1118 |
kidney | 100% | 169.84 | 89 / 89 | 0% | 0 | 0 / 901 |
lung | 100% | 235.21 | 578 / 578 | 0% | 0 | 0 / 1155 |
ovary | 100% | 228.67 | 180 / 180 | 0% | 0 | 0 / 430 |
prostate | 100% | 359.11 | 245 / 245 | 0% | 0 | 0 / 502 |
spleen | 100% | 314.75 | 241 / 241 | 0% | 0 | 0 / 0 |
thymus | 100% | 180.21 | 653 / 653 | 0% | 0 | 0 / 605 |
uterus | 100% | 229.82 | 170 / 170 | 0% | 0 | 0 / 459 |
adipose | 100% | 187.75 | 1203 / 1204 | 0% | 0 | 0 / 0 |
intestine | 100% | 206.14 | 963 / 966 | 0% | 0 | 0 / 527 |
blood vessel | 100% | 195.44 | 1329 / 1335 | 0% | 0 | 0 / 0 |
esophagus | 99% | 192.48 | 1429 / 1445 | 0% | 0 | 0 / 183 |
brain | 98% | 176.67 | 2589 / 2642 | 0% | 0 | 0 / 705 |
skin | 98% | 115.74 | 1764 / 1809 | 0% | 0 | 0 / 472 |
stomach | 97% | 121.67 | 350 / 359 | 0% | 0 | 0 / 286 |
adrenal gland | 95% | 99.63 | 246 / 258 | 0% | 0 | 0 / 230 |
heart | 92% | 90.37 | 794 / 861 | 0% | 0 | 0 / 0 |
pancreas | 92% | 75.05 | 301 / 328 | 0% | 0 | 0 / 178 |
liver | 91% | 98.56 | 206 / 226 | 0% | 0 | 0 / 406 |
peripheral blood | 79% | 98.94 | 732 / 929 | 0% | 0 | 0 / 0 |
muscle | 58% | 34.03 | 466 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0007218 | Biological process | neuropeptide signaling pathway |
GO_0007268 | Biological process | chemical synaptic transmission |
GO_0060079 | Biological process | excitatory postsynaptic potential |
GO_0043204 | Cellular component | perikaryon |
GO_0005615 | Cellular component | extracellular space |
GO_0043679 | Cellular component | axon terminus |
GO_0005576 | Cellular component | extracellular region |
GO_0098794 | Cellular component | postsynapse |
GO_0030425 | Cellular component | dendrite |
GO_0001664 | Molecular function | G protein-coupled receptor binding |
GO_0005102 | Molecular function | signaling receptor binding |
GO_0005184 | Molecular function | neuropeptide hormone activity |
Gene name | NPFF |
Protein name | Pro-FMRFamide-related neuropeptide FF (FMRFamide-related peptides) [Cleaved into: Neuropeptide SF (NPSF); Neuropeptide FF (NPFF); Neuropeptide AF (NPAF)] |
Synonyms | |
Description | FUNCTION: Morphine modulating peptides. Have wide-ranging physiologic effects, including the modulation of morphine-induced analgesia, elevation of arterial blood pressure, and increased somatostatin secretion from the pancreas. Neuropeptide FF potentiates and sensitizes ASIC1 and ASIC3 channels. . |
Accessions | O15130 ENST00000267017.4 [O15130-1] |